Toronto, Ontario–(Newsfile Corp. – November 7, 2024) – HearAtLast Holdings, Inc. (OTC Pink: HRAL), is excited to work with Hohm in a multi-million dollar industry for portable home pods. This is a new way of giving households the extra space they need. This will also help homeless people across North America, providing a temporary home with all capabilities.
Pete Wanner, President of Hear AtLast Holdings, expressed that, Hear AtLast can talk to municipalities and government officials about using these pods for temporary use across the country. Hohm Pods is a multi-million dollar business that can spread quickly to solve many problems the country has with homeless and immigrants. The company is eager to start with the display units and distributing these across the country.
About Hear AtLast Holdings, Inc, (OTC Pink: HRAL)
The holding company that operates GetPushMonkey.com, an AI notification platform which improves user engagement, provide personalized experiences, and optimize the effectiveness of your push notifications. Utilizing AI algorithms to analyze user behavior, preferences, and browsing history to tailor notifications to individual users. This can result in more relevant and engaging notifications that users are more likely to interact with which can result in increased company profits.
Contact Information:
Hear AtLast Holdings Inc
Pete Wanner, President
Tel: 416-918-6987
petewanner@gmail.com
SOURCE: Hear AtLast Holdings, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229104
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…